Diagnostic utility of PAX8 in differentiation of mullerian from non-mullerian tumors

Authors
Mitra Heidarpour
Zahra Tavanafar
Department of Pathology, Isfahan University of Medical Sciences, Isfahan, Iran
Abstract
Background: Considering the high prevalence of female genital tract neoplasms, non-specific nature of the initial symptoms, higher possibility of metastasis by the time of diagnosis, importance of differentiating metastatic Mullerian tumors or metastatic breast cancer in the female genital tract, especially in the ovary, and lack of diagnostic markers with high sensitivity and specificity, the purpose of the current study was to evaluate the utility of Paired box protein8 (PAX8) expression in Mullerian and non-Mullerian neoplasms.
Materials and Methods: In this descriptive-analytic, cross-sectional study, paraffin-embedded tissues of patients with definitive pathologic diagnosis of Mullerian and non-Mullerian tumors were selected. PAX8 immunohistochemical (IHC) staining was performed for all selected blocks. Immunopositivity of the slides for PAX8 was reviewed. It was defined as the presence of nuclear staining in at least 10% of the tumor cell nuclei.
Results: Thirty-seven Mullerian (including 18 ovarian epithelial tumors, 17 endometrial carcinoma and two endocervical adenocarcinoma) and 37 non-Mullerian tumors were studied for PAX8 expression. Twenty-nine of 37 (78.4%) and one of 37 (2.7%) of the Mullerian and non-Mullerian tumors were positive for PAX8, respectively. The sensitivity and specificity of PAX8 by IHC for differentiation of Mullerian from non-Mullerian tumors was 78.4% and 97.3%, respectively.
Conclusion: Our findings indicated that PAX8 could be used as a useful IHC marker for diagnosing Mullerian tumors. It has moderate to high sensitivity, but high specificity, for diagnosing carcinomas of Mullerian origin.

Keywords

1. Micci F, Weimer J, Haugom L, Skotheim RI, Grunewald R, Abeler VMet al. Reverse painting of microdissected chromosome 19 markers in ovarian carcinoma identifies a complex rearrangement map. Genes Chromosomes Cancer 2009;48:184-93.  Back to cited text no. 1
    
2. Goff BA, Mandel LS, Melancon CH, Muntz HG. Frequency of symptoms of ovarian cancer in women presenting to primary care clinics. JAMA 2004;291:2705-12.  Back to cited text no. 2
    
3. Zhu W, Michael CW. WT1, monoclonal CEA. TTF1, and CA125 antibodies in the differential diagnosis of lung, breast, and ovarian adenocarcinomas in serous effusions. Diagn Cytopathol 2007;35:370-5.  Back to cited text no. 3
    
4. Lee BH, Hecht JL, Pinkus JL, Pinkus GS. WT1, estrogen receptor,and progesterone receptor as markers for breast or ovarian primary sites in metastatic adenocarcinoma to body fluids. Am J Clin Pathol 2002;117: 745-50.  Back to cited text no. 4
    
5. Köbel M, Kalloger SE, Carrick J, Huntsman D, Asad H, Oliva E, et al. A limited panel of immunomarkers can reliably distinguish between clear cell and high-grade serous carcinoma of the ovary. Am J Surg Pathol 2009;33:14-21.  Back to cited text no. 5
    
6. Ozcan A, Liles N, Coffey D, Shen SS, Truong LD. PAX2 and PAX8 expression in primary and metastatic müllerian epithelial tumors: A comprehensive comparison. Am J Surg Pathol 2011;35:1837-47.  Back to cited text no. 6
    
7. Wiseman W, Michael CW, Roh MH. Diagnostic utility of PAX8 and PAX2 immunohistochemistry in the identification of metastatic Müllerian carcinoma in effusions. Diagn Cytopathol 2011;39:651-6.   Back to cited text no. 7
    
8. Tong GX, Devaraj K, Hamele-Bena D, Yu WM, Turk A, Chen X, Wright JD, et al. Pax8: A marker for carcinoma of Müllerian origin in serous effusions. Diagn Cytopathol 2011;39:567-74.   Back to cited text no. 8
    
9. Chi N, Epstein JA. Getting your Pax straight: Pax proteins in development and disease. Trends Genet 2002;18:41-7.  Back to cited text no. 9
    
10. Poleev A, Fickenscher H, Mundlos S, Winterpacht A, Zabel B, Fidler A, et al. PAX8, a human paired box gene: Isolation and expression in developing thyroid, kidney and Wilms′ tumors. Development 1992;116:611-23.  Back to cited text no. 10
    
11. Bowen NJ, Logani S, Dickerson EB, Kapa LB, Akhtar M, Benigno BB, et al. Emerging roles for PAX8 in ovarian cancer and endosalpingeal development. Gynecol Oncol 2007;104:331-7.   Back to cited text no. 11
    
12. Nonaka D, Chiriboga L, Soslow RA. Expression of pax8 as a useful marker in distinguishing ovarian carcinomas from mammary carcinomas. Am J Surg Pathol 2008;32:1566-71.  Back to cited text no. 12
    
13. Tacha D, Zhou D, Cheng L. Expression of PAX8 in normal and neoplastic tissues: A comprehensive immunohistochemical study. Appl Immunohistochem Mol Morphol 2011;19:293-9.  Back to cited text no. 13
    
14. Ozcan A, Shen SS, Hamilton C, Anjana K, Coffey D, Krishnan B, et al. PAX 8 expression in non-neoplastic tissues, primary tumors, and metastatic tumors: A comprehensive immunohistochemical study. Mod Pathol 2011;24:751-64.   Back to cited text no. 14
    
15. McCluggage WG, Young RH. Immunohistochemistry as a diagnostic aid in the evaluation of ovarian tumors. Semin Diagn Pathol 2005;22:3-32.  Back to cited text no. 15
    
16. Li J, Abushahin N, Pang S, Xiang L, Chambers SK, Fadare O, et al. Tubal origin of ′ovarian′ low-grade serous carcinoma. Mod Pathol 2011;24:1488-99.   Back to cited text no. 16
    
17. Laury AR, Perets R, Piao H, Krane JF, Barletta JA, French C, et al. A comprehensive analysis of PAX8 expression in human epithelial tumors. Am J Surg Pathol 2011;35:816-26.  Back to cited text no. 17
Advanced Biomedical Research
Volume 2014, March
March 2014
Pages 1-4